Analyst Consensus ?
ConsensusBuy26 ratings
Bullish2492.3%
Neutral27.7%
Bearish00.0%
Ascendis Pharma A/S · ASND · FY2024 Q3 · Calendar Q4 2024
Ascendis highlights SKYTROFA growth, launches and pipeline milestones
The supplied analysis supports a constructive but conditional view: SKYTROFA volume growth, YORVIPATH commercialization, pipeline milestones and the Novo Nordisk collaboration could broaden Ascendis' growth drivers, while regulatory, payer, competitive and execution risks remain material.
Reported Before market openNASDAQHealthcare
$14.05B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $-1.90
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $88.3M
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-1.4%
Event window
SPY move
-0.6%
Same window
Abnormal move
-0.7%
Stock minus SPY
Volume
2.8×
Versus trailing sessions
Subsequent drift
+4.5%
Up to 20 sessions
ASNDSPY benchmark
Ask FN2 about ASND FY2024 Q3
Transcript, numbers and history already loaded
What drove ASND's -1.4% move after FY2024 Q3 earnings?What changed in ASND's guidance and outlook in FY2024 Q3?Give me the bull and bear case for ASND after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the prior-quarter analysis, the supplied call analysis emphasized stronger SKYTROFA volume growth, a nearer-term YORVIPATH US launch, a targeted TransCon CNP NDA filing, a Novo Nordisk collaboration and a higher reported cash balance. Guidance sentiment remained maintained.
Guidance delta
Management analysis indicates guidance was maintained; no new quantitative guidance change was supplied.
Key takeaways
- Management analysis characterized SKYTROFA volume growth as exceeding 60% year over year.
- The US YORVIPATH launch was targeted for mid-January 2025, with expanded commercial support.
- TransCon CNP NDA filing was targeted for Q1 2025, alongside additional development plans.
- A Novo Nordisk collaboration added an upfront payment and royalties for a once-monthly GLP-1 program.
- Management analysis cited cash of €626 million and a goal of operating cash-flow breakeven by end-2025.
Management priorities
- Commercialize YORVIPATH in the US and expand in Europe.
- Advance TransCon CNP toward the planned NDA filing and pursue additional indications.
- Expand SKYTROFA labels and progress the COACH combination trial.
- Develop the once-monthly GLP-1 program with Novo Nordisk.
Follow ASND with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$225.25Current
$136Low
$270.03Average
$344High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 18, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Sep 25, 2026 |
| Raymond James | Outperform | Strong Buy | Downgrade | Sep 15, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Sep 2, 2026 |
| Wedbush | Outperform | Outperform | Maintain | Sep 1, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Sep 1, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 31, 2026 |
| Jefferies | Buy | Buy | Maintain | Aug 31, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Aug 31, 2026 |
| B of A Securities | Buy | Buy | Maintain | Aug 31, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 14, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 14, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 14, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 15, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 8, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 9, 2025 |
| UBS | Buy | Buy | Maintain | Aug 8, 2025 |
| Citigroup | Buy | Buy | Maintain | Aug 8, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 13, 2025 |
| Credit Suisse | Neutral | Neutral | Maintain | Apr 28, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jan 17, 2023 |
| Cowen & Co. | Perform | Market Perform | Maintain | Jan 6, 2022 |
| Canaccord Genuity | Buy | Buy | Maintain | Jun 1, 2021 |
| Berenberg | Buy | Buy | Maintain | Dec 17, 2020 |
| Leerink Swann | Outperform | Market Perform | Upgrade | Jan 24, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Aug 30, 2018 |
| Bank of America | Buy | Buy | Maintain | Jan 25, 2018 |
Named analyst price targets
Upside is calculated against the persisted current price $225.25. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $269 | $227 | +19.4% | Oct 15, 2026 |
| UBS | Analyst unavailable | $344 | $239.77 | +52.7% | Sep 16, 2026 |
| Raymond James | Martin Auster | $287 | $264.92 | +27.4% | Sep 15, 2026 |
| H.C. Wainwright | Analyst unavailable | $344 | $260.81 | +52.7% | Sep 10, 2026 |
| Oppenheimer | Leland Gershell | $312 | $260.25 | +38.5% | Sep 1, 2026 |
| Morgan Stanley | Maxwell Skor | $273 | $263.04 | +21.2% | Sep 1, 2026 |
| Jefferies | Analyst unavailable | $330 | $265.26 | +46.5% | Aug 31, 2026 |
| Stifel Nicolaus | Analyst unavailable | $326 | $265.32 | +44.7% | Aug 31, 2026 |
| UBS | Analyst unavailable | $345 | $247.91 | +53.2% | Aug 31, 2026 |
| H.C. Wainwright | Analyst unavailable | $345 | $250.25 | +53.2% | Aug 27, 2026 |
| BMO Capital | Analyst unavailable | $319 | $248.85 | +41.6% | Aug 18, 2026 |
| RBC Capital | Luca Issi | $290 | $247.06 | +28.7% | Aug 14, 2026 |
| Barclays | Analyst unavailable | $329 | $246.23 | +46.1% | Aug 14, 2026 |
| Jefferies | Kelly Shi | $333 | $246.23 | +47.8% | Aug 13, 2026 |
| Morgan Stanley | Analyst unavailable | $275 | $253.6 | +22.1% | Jul 23, 2026 |
| RBC Capital | Analyst unavailable | $280 | $267.92 | +24.3% | Jul 7, 2026 |
| Evercore ISI | Analyst unavailable | $329 | $241.83 | +46.1% | May 15, 2026 |
| Barclays | Analyst unavailable | $345 | $238.66 | +53.2% | May 11, 2026 |
| Wells Fargo | Analyst unavailable | $326 | $246.14 | +44.7% | May 8, 2026 |
| Jefferies | Analyst unavailable | $262 | $237.35 | +16.3% | Mar 5, 2026 |
| Stifel Nicolaus | Alex Thompson | $332 | $241.38 | +47.4% | Mar 4, 2026 |
| Wolfe Research | Kalpit Patel | $260 | $231.46 | +15.4% | Mar 2, 2026 |
| Cantor Fitzgerald | Li Watsek | $300 | $231.43 | +33.2% | Mar 2, 2026 |
| Evercore ISI | Josh Schimmer | $324 | $234.07 | +43.8% | Mar 2, 2026 |
| Goldman Sachs | Paul Choi | $255 | $233.5 | +13.2% | Mar 2, 2026 |
| Wedbush | Analyst unavailable | $273 | $218.39 | +21.2% | Feb 12, 2026 |
| Oppenheimer | Analyst unavailable | $262 | $217.93 | +16.3% | Feb 12, 2026 |
| Stifel Nicolaus | Alex Thompson | $325 | $218.04 | +44.3% | Feb 12, 2026 |
| Morgan Stanley | Maxwell Skor | $256 | $221.49 | +13.7% | Feb 12, 2026 |
| Barclays | Eliana Merle | $342 | $238.8 | +51.8% | Jan 27, 2026 |
| RBC Capital | Analyst unavailable | $250 | $205.83 | +11.0% | Jan 20, 2026 |
| Wells Fargo | Derek Archila | $330 | $205.83 | +46.5% | Jan 20, 2026 |
| Wells Fargo | Analyst unavailable | $322 | $208.75 | +43.0% | Jan 9, 2026 |
| Stifel Nicolaus | Alex Thompson | $256 | $201.37 | +13.7% | Dec 11, 2025 |
| Cantor Fitzgerald | Li Watsek | $254 | $209.55 | +12.8% | Oct 13, 2025 |
| RBC Capital | Luca Issi | $230 | $191.49 | +2.1% | Aug 8, 2025 |
| Morgan Stanley | Analyst unavailable | $180 | $144.08 | -20.1% | Feb 18, 2025 |
| Bank of America Securities | Tazeen Ahmad | $191 | $151.26 | -15.2% | Sep 23, 2024 |
| Evercore ISI | Gavin Clark-Gartner | $205 | $144.97 | -9.0% | Sep 17, 2024 |
| Oppenheimer | Leland Gershell | $190 | $143.9 | -15.6% | Sep 17, 2024 |
| Citigroup | David Lebowitz | $207 | $139.57 | -8.1% | Sep 17, 2024 |
| Wells Fargo | Derek Archila | $289 | $139.57 | +28.3% | Sep 17, 2024 |
| Bank of America Securities | Tazeen Ahmad | $175 | $142.26 | -22.3% | Sep 16, 2024 |
| Goldman Sachs | Paul Choi | $200 | $142.26 | -11.2% | Sep 16, 2024 |
| Citigroup | David Lebowitz | $178 | $118 | -21.0% | Sep 13, 2024 |
| Oppenheimer | Leland Gershell | $180 | $122.4 | -20.1% | Sep 5, 2024 |
| Jefferies | Kelly Shi | $196 | $128.48 | -13.0% | Aug 13, 2024 |
| Stifel Nicolaus | Alex Thompson | $200 | $137.45 | -11.2% | May 30, 2024 |
| Morgan Stanley | Vikram Purohit | $140 | $124.04 | -37.8% | May 15, 2024 |
| Evercore ISI | Josh Schimmer | $191 | $149.89 | -15.2% | Mar 14, 2024 |
| Wells Fargo | Analyst unavailable | $177 | $118.87 | -21.4% | Jan 3, 2023 |
| Morgan Stanley | Analyst unavailable | $148 | $111.47 | -34.3% | Nov 15, 2022 |
| Leerink Partners | Analyst unavailable | $148 | $110.26 | -34.3% | Nov 14, 2022 |
| Wedbush | Analyst unavailable | $164 | $110.26 | -27.2% | Nov 14, 2022 |
| Bank of America Securities | Tazeen Ahmad | $161 | $117.44 | -28.5% | Mar 20, 2022 |
| Citigroup | David Lebovitz | $187 | $112.39 | -17.0% | Feb 28, 2022 |
| Cowen & Co. | Yaron Werber | $136 | $121.7 | -39.6% | Jan 6, 2022 |
| Canaccord Genuity | Michelle Gilson | $196 | $126.68 | -13.0% | Jul 7, 2021 |
| Cantor Fitzgerald | Alethia Young | $201 | $134.4 | -10.8% | Jun 14, 2021 |
Track every rating change on ASND the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAscendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Historical context
All ASND earningsLatest beats and misses
Who reports nextBeat on EPS
Get the ASND recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:39:04.055137+00:00
- Polygon adjusted daily market bars · 2026-10-18T01:00:41.796953+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-18T01:00:41.794054+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-18. For educational purposes only; not investment advice.